Con A affinity of rat alpha 1-acid glycoprotein (rAGP): changes during inflammation, dexamethasone or phenobarbital treatment as detected by crossed affino immunoelectrophoresis (CAIE) are not only a reflection of biantennary glycan content.
Using crossed affino immunoelectrophoresis (CAIE), the secretion of the Con A most reactive form (CAIE-3) of rat alpha 1-acid glycoprotein (rAGP) has been shown to be increased in sera of Wistar and Sprague Dawley rats during inflammation and treatment with dexamethasone or phenobarbital. Primary hepatocyte cultures prepared from experimentally treated Wistar rats reflect these in vivo findings, since rAGP as present in corresponding secretion media shows similar changes in Con A reactivity. In this study, the relation of this increase towards the amount of biantennary glycans was investigated for both differently treated rat strains. For this purpose, metabolically labelled rAGP, secreted by isolated hepatocytes under the various conditions, was separated on Con A-Sepharose into four fractions. For each fraction of rAGP its behaviour in CAIE was established, revealing a positive correlation for Con A reactivity between the two methods. However, the enormous increase in Con A reactivity of rAGP in CAIE during inflammation and other conditions (increase in CAIE-3), could not be shown using Con A-Sepharose chromatography. Glycopeptides of each fraction were prepared and the amount of biantennary glycans was assessed. Contrary to expectations, an increase of the total amount of biantennary glycans of rAGP, secreted during conditions associated with an increase in CAIE-3 was not found. The independency of the results with regard to rat strain and procedures used underlined the generality of these findings. Consequently, not only the biantennary glycan content is responsible for the separation of rAGP in CAIE. The importance of other differences in glycosylation, e.g. sialylation, for the increase of rAGP CAIE-3 during various experimental conditions is discussed.
Pos
O
O
Department of Medical Chemistry, Faculty of Medicine, Vrije Universiteit, Amsterdam, The Netherlands.
Drechou
A
A
Durand
G
G
Bierhuizen
M F
MF
van der Stelt
M E
ME
van Dijk
W
W
D000209:Acute-Phase Proteins / Q000032:analysis; D000818:Animals; D002847:Chromatography, Agarose; D003208:Concanavalin A / Q000378:metabolism*; D003907:Dexamethasone / Q000494:pharmacology*; D007123:Immunoelectrophoresis, Two-Dimensional; D007249:Inflammation / Q000503:physiopathology*; D008099:Liver / Q000032:analysis / Q000166:cytology / Q000187:drug effects; D008297:Male; D009961:Orosomucoid / Q000032:analysis* / Q000145:classification / Q000378:metabolism; D010634:Phenobarbital / Q000494:pharmacology*; D011134:Polysaccharides / Q000032:analysis*; D051381:Rats; D011919:Rats, Inbred Strains
D000209:Acute-Phase Proteins; D009961:Orosomucoid; D011134:Polysaccharides; D003208:Concanavalin A; D003907:Dexamethasone; D010634:Phenobarbital